Vor Biopharma
55 hedge funds and large institutions have $332M invested in Vor Biopharma in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 19 increasing their positions, 2 reducing their positions, and 10 closing their positions.
850% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 2
242.42% more ownership
Funds ownership: 2.97% → 245.39% (+242%)
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
173% more call options, than puts
Call options by funds: $16.2M | Put options by funds: $5.93M
81% more capital invested
Capital invested by funds: $183M → $332M (+$149M)
49% more funds holding
Funds holding: 37 → 55 (+18)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$63.7M |
| 2 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$60.3M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$47.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.6M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$32.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Ariose Capital Management
Central, Hong Kong,
Hong Kong
|
-$5.37M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.44M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.33M |
| 4 |
PCMH
Polymer Capital Management (HK)
Hong Kong
|
-$1.04M |
| 5 |
Renaissance Technologies
New York
|
-$711K |
VOR Hedge Fund Activity: Q4 2025 in Review
55 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q4 2025, worth a combined $332M — up 81% from $183M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VOR positions and 10 closed out — a net gain of 18 holders — while 19 added to existing stakes and 2 trimmed.
The largest buyer was RA Capital Management, adding an estimated $63.7M. The largest seller was Ariose Capital Management, exiting entirely with an estimated $5.37M sold.
- 55 institutional investors held Vor Biopharma (VOR) as of Q4 2025, up from 37 in Q3 2025.
- Funds reported $332M of Vor Biopharma stock for Q4 2025, up 81% quarter-over-quarter.
- 28 funds opened new Vor Biopharma positions in Q4 2025 and 10 closed out, a net change of +18 holders.
- The largest Vor Biopharma buyer in Q4 2025 was RA Capital Management, an estimated $63.7M added.
- The largest Vor Biopharma seller in Q4 2025 was Ariose Capital Management, an estimated $5.37M sold.
Based on aggregated 13F filings for Q4 2025.